Capsule Bag Performance of a Novel Single-piece Acrylic IOL HOYA AF-1 NY-60
NCT ID: NCT07167589
Last Updated: 2025-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
42 participants
INTERVENTIONAL
2011-02-01
2013-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study the capsule performance and stability of a new one-piece microincisional hydrophobic acrylic IOL (HOYA AF-1 NY-60) should be assessed in subgroups of normal, short and long eyes. The IOL has a sharp optic edge design to inhibit PCO formation. Hypothesis: The novel haptic design is supposed to avoid tension folds in capsule bag, allow for a longer contact length of haptic with capsule equator, ensure rotational stability as well as good centration of the optic.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Posterior Capsule Opacification and Optical Quality of Different Hydrophobic Acrylic Intraocular Lenses
NCT03831074
Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two Microincision IOLs: Hoya iMics NY-60 vs Acrysof SN60WF
NCT01732484
Posterior Capsule Opacification Development With Two Different Intraocular Lenses
NCT01734343
Cell Ongrowth and Biocompatibility Study of Two Different (Hydrophobic Acrylic) Intraocular Lenses: IOL XY1 vs. IOL XY1A
NCT06708806
Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties
NCT01767012
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HOYA acrylic single-piece IOL (HOYA AF-1 NY-60)
Cataract surgery with implantation of a single-piece microincisional IOL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cataract surgery with implantation of a single-piece microincisional IOL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 21 and older
* Visual Acuity \> 0.05
* Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
Exclusion Criteria
* Preceding ocular surgery or trauma
* In case of pregnancy (pregnancy test will be taken preoperatively in women of reproductive age)
21 Years
105 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vienna Institute for Research in Ocular Surgery
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prim. Prof. Dr. Oliver Findl, MBA
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vienna Institute for Research in Ocular Surgery
Vienna, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Viros_HOYA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.